Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: N/E PATSFAN who wrote (96)	2/16/2000 11:02:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

[ NEPF/Mysterians ] >> Rick, aren't you disappointed with KDUS's performance today based on the licensing agreement with OSIP (other than the increase in value to your "stake" in OSIP)? << I have no concept of why OSIP popped, but this news didn't appear until well after the close, and KDUS is BB. >> If KDUS retained the rights for further licensing why wasn't it rewarded unless the perception is that the fees weren't very lucrative? << I'm certain that they weren't all that lucrative, up front. But, again, the release came out well beyond the close. Study the business plan..... does one buy a HGSI or a MLNM for current income? The name of the game in biotech investing is leverage. When you find leverage combined with relative safety, a "buy" usually represents wisdom. HGSI described a single patent today, covering a single gene, coding for a single G-protein coupled receptor. HGSI added $1.54 billion to market cap on the news. KDUS offers a platform for GPCR-based functional genomics, first license taken today, and you can buy the ENTIRE float for less than $2 million. I'm not going to reiterate what one gets for a capitalization of $20 million and a cap:book of less than 3. It's largely in this thread and the SEC disclosures. >> Disclosure > I haven't bot KDUS yet and now wonder if OSIP isn't the better play esp @ lower prices. << Wait a bit, and you can buy my KDUS. >> btw, is the current business plan to license assets to build cash for other products? << Wow. A couple of days ago, I would have said "no, are you nuts?" Now, I think that the answer is yes. We need to find a Sangamo-like company in Europe that wants to buy the platform before it is further licensed. But, either way, it's north from here. The first deal with OSIP? They bought specific molecules. Today's deal? Looking at the molecules, they realize the power of the platform. Enough? Sorry, it's time for synapse overload.... why would OSIP license the library, given the Sibia victory in court? One of two answers are likely..... (1) OSIP (nee KDUS) scientists could have identified a route around the readout issue, or (2) OSIP (nee KDUS) scientists, now aligned with Pfizer (also a litigant against Sibia), are thumbing their nose at Sibia. Cheers! Rick